Naproxen: Difference between revisions
(Text replacement - "*CHF" to "*CHF") |
(Text replacement - "OR" to "'''OR'''") |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*500mg PO BID OR 250mg q6-8h | *500mg PO BID '''OR''' 250mg q6-8h | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*5mg/kg BID | *5mg/kg BID | ||
Revision as of 01:41, 31 May 2017
Administration
- Type: NSAID
- Dosage Forms:
- Routes of Administration: PO
- Common Trade Names: Aleve
Adult Dosing
- 500mg PO BID OR 250mg q6-8h
Pediatric Dosing
- 5mg/kg BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: infant risk minimal
Renal Dosing
- Adult: Not recommended if CrCl <30
- Pediatric:
Hepatic Dosing
- Adult: use lowest effective dose
- Pediatric:
Contraindications
- Allergy to class/drug
- peri-CABG
Adverse Reactions
Serious
- GI bleed, gastric ulcer
- Nephrotoxicity
- Angioedema
- Bronchospasm
- CHF, pulmonary edema
- Thrombocytopenia, aplastic anemia, hemolytic anemia, agranulocytosis
- Vasculitis
- SJS/TEN
- Hepatotoxicity (hepatitis, liver failure)
- Aseptic meningitis, seizure
Common
- Nausea, heartburn, constipation
- Edema
- Ecchymosis
- Headache
- Ototoxicity
Pharmacology
- Half-life: 12-17 hours
- Metabolism:
- Excretion: Renal
Mechanism of Action
- NSAID